乳腺癌肝转移机制研究进展

doi:10.11904/j.issn.1002-3070.2017.01.010

Abstract

Abstract: Liver is the common metastatic site of breast cancer.The process of liver metastasis consists of multiple steps and involves various factors from breast cancer cells and the liver micro-environment.In this review,we reviewed the molecular(including the connection of proteins,protein kinases,miRNAs),signal transduction pathways(including CXCL12-CXCR4 axis,Wnt/beta-catenin signaling pathway,AF1q/TCF7/CD44 regulatory axis,laminin receptor/Akt/ERK signaling pathway,leptin/ERK/IL-8 signaling pathway)and the influencing factors(including hypoxia inducible factors,tumor-associated fibroblasts,adipose tissue matrix stem cells,metalloproteinases,selective ligands,inflammatory cell infiltration)associated with the liver micro-environment in breast cancer.

Key words: Breast cancer, Liver metastasis, Micro-environment

CLC Number:

R737.9

LI Bo, CHEN Xuesong. Mechanisms involved in liver metastasis of breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 48-52.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2017.01.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2017/V31/I1/48

References

1 Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
2 Ma R,Feng Y,Lin S,et al.Mechanisms involved in breast cancer liver metastasis[J].J Transl Med,2015,15(13):64.
3 Kimbung S,Kovács A,Bendahl PO,et al.Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences[J].Mol Oncol,2014,8(1):119-128.
4 Tabariès S,Annis MG,Hsu BE,et al.Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis[J].Oncotarget,2015,6(11):9476-9487.
5 Tabariès S,Dupuy F,Dong Z,et al.Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes[J].Mol Cell Biol,2012,32(15):2979-2991.
6 Tabariès S,Dong Z,Annis MG,et al.Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes[J].Oncogene,2011,30(11):1318-1328.
7 Shabo I,Olsson H,Stl O,et al.Breast cancer expression of DAP12 is associated with skeletal and liver metastases and poor survival[J].Clin Breast Cancer,2013,13(5):371-377.
8 Kim HM,Jung WH,Koo JS.Expression of cancer-associated fibroblast related proteins in metastatic breast cancer:an immunohistochemical analysis[J].Transl Med,2015,13(1):1-11.
9 van Roosmalen W,Le Dévédec SE,Golani O,et al.Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant[J].J Clin Invest,2015,125(4):1648-1664.
10 Dupuy F,Tabariès S,Andrzejewski S,et al.PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer[J].Cell Metab,2015,22(4):577-589.
11 Endres M,Kneitz S,Orth MF,et al.Regulation of matrix metalloproteinases(MMPs)expression and secretion in MDA-MB-231 breast cancer cells by LIM and SH3 protein 1(LASP1)[J].Oncotarget,2016,7(39):64244-64259.
12 Li X,Liu X,Xu W,et al.c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2[J].J Biol Chem,2013,288(25):18121-18133.
13 Salomonnson E,Stacer AC,Ehrlich A,et al.Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy[J].PLoS One,2013,8(1):e51500.
14 Cavallaro S.CXCR4/CXCL12 in non-small-cell lung cancer metastasis to the brain[J].Int J Mol Sci,2013,14(1):1713-1727.
15 Sun Y,Mao X,Fan C,et al.CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis[J].Tumour Biol,2014,35(8):7765-7773.
16 Bleckmann A,Conradi LC,Menck K,et al.β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases[J].Clin Exp Metastasis,2016,33(4):309-323.
17 Park J,Schlederer M,Schreiber M,et al.AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis[J].Oncotarget,2015,6(24):20697-20710.
18 Hong H,Zhou T,Fang S,et al.Pigment epithelium-derived factor(PEDF)inhibits breast cancer metastasis by down-regulating fibronectin[J].Breast Cancer Res Treat,2014,148(1):61-72.
19 Cao H,Huang Y,Wang L,et al.Leptin promotes migration and invasion of breast cancer cells by stimulating IL-8 production in M2 macrophages[J].Oncotarget,2016,7(40):65441-65453.
20 Semenza GL.HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations[J].J Clin Invest,2013,123(9):3664-3671.
21 Mi Z,Bhattacharya SD,Kim VM,et al.Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis[J].Carcinogenesis,2011,32(4):477-487.
22 Ghattass K,El-Sitt S,Zibara K,et al.The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway[J].Mol Cancer,2014,24(13):12.
23 Madsen CD,Pedersen JT,Venning FA,et al.Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis[J].EMBO Rep,2015,16(10):1394-1408.
24 Strong AL,Ohlstein JF,Biagas BA,et al.Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers[J].Breast Cancer Res,2015,19(17):112.
25 Freitas VM,do Amaral JB,Silva TA,et al.Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion[J].Mol Cancer,2013,5(12):2.
26 Choi GC,Li J,Wang Y,et al.The metalloprotease ADAMTS8 displays anti-tumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation[J].Mol Cancer Res,2014,12(2):228-238.
27 Kelwick R,Wagstaff L,Decock J,et al.Metalloproteinase-dependent and-independent processes contribute to inhibition of breast cancer cell migration,angiogenesis and liver metastasis by a disintegrin and metalloproteina-se with thrombospondinmotifs-15[J].Int J Cancer,2015,136(4):14-26.
28 Woodman N,Pinder SE,Tajadura V,et al.Two E-selectin ligands,BST-2 and LGALS3BP,predict metastasis and poor survival of ER-negative breast cancer[J].Int J Oncol,2016,49(1):265-275.
29 Tabariès S,Ouellet V,Hsu BE,et al.Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases[J].Breast Cancer Res,2015,27(17):45.

[1]	LI Xudong, LIU Tong. The single cell transcriptome sequencing reveals the role and prognostic value of PCLAF and ERO1A in the progression of breast cancer [J]. Journal of Practical Oncology, 2025, 39(5): 418-427.
[2]	MA Dongqiong, YANG Cangjiang, ZHU Yunfang, WEN Hongmei, CAO Jidong, DAI Tangyan, LEI Guoyan, LI Dongke, SHI Qingping. Incidence and mortality of female breast cancer in cancer registration areas of Yunnan Province in 2020 and trend analysis from 2012 to 2020 [J]. Journal of Practical Oncology, 2025, 39(4): 272-277.
[3]	LUO Danli, LI Fucheng, JIA Siyuan, DOU He, BA Yuling, GAO Tian, LI Zhaoting, XIAO Min. Effect of plasma atherosclerosis index on pathological complete response and prognosis of breast cancer patients treated with neoadjuvant chemotherapy [J]. Journal of Practical Oncology, 2025, 39(4): 316-323.
[4]	WU Dan, WANG Yihai. Current status of radiotherapy resistance research in breast cancer [J]. Journal of Practical Oncology, 2025, 39(3): 262-266.
[5]	WANG Rui, MA Deyuan, JIA Wangqiang, GUAN Quanlin. Application and progress of nano-medicine mediated cuproptosis in the breast cancer treatment [J]. Journal of Practical Oncology, 2025, 39(2): 144-150.
[6]	WANG Shuai, LI Qiqing, LI Rui, XU Tiefeng. Advances in the application of nanoparticles in the diagnosis and treatment of breast cancer [J]. Journal of Practical Oncology, 2025, 39(2): 151-156.
[7]	WANG Ru, ZHANG Hongxia. Research progress on the application of magnetic resonance imaging technology in predicting lymphatic vascular invasion in breast cancer [J]. Journal of Practical Oncology, 2025, 39(2): 162-168.
[8]	GU Wen, ZHOU Lan, JIA Yanni, HUANG Weidong. Validation of measurement attributes for QLU-C10D scale in breast cancer patients [J]. Journal of Practical Oncology, 2025, 39(1): 49-55.
[9]	SHI Changyong, ZHOU Zizhen, ZHOU Guanglin, XIONG Yimin. The values of DCE-MRI quantitative parameters combined with NCAPH in the diagnosis of early breast cancer [J]. Journal of Practical Oncology, 2025, 39(1): 56-60.
[10]	ZHANG Yuqing, JING Jing, LIU Zhaoliang, AN Jing, AN Weiwei. The alternative splicing event of MZB1 is a potential biomarker of drug resistance in endocrine therapy of breast cancer [J]. Journal of Practical Oncology, 2024, 38(5): 313-322.
[11]	YANG Minye, XIAN Tongcheng, LIU Jingjian, BIE Jun, WANG Jie, LUO Yi. The expression of IL-23 in breast cancer tissues and its correlation with clinicopathological characteristics [J]. Journal of Practical Oncology, 2024, 38(5): 323-329.
[12]	LIU Dong, ZHANG Taijuan, DANG Jifeng. The research progress of inflammatory reaction driving breast cancer metastasis [J]. Journal of Practical Oncology, 2024, 38(5): 336-341.
[13]	LI Qianni, XU Lingyan, LI Jian, YAO Xuepei, LIU Meina. Trend analysis of a longitudinal evaluation for multidimensional treatment quality of breast cancer [J]. Journal of Practical Oncology, 2024, 38(4): 213-220.
[14]	GAO Guangqiang, WANG Falin, LI Juan, TIAN Hong, GUO Sijia, YU Xiaolan, YANG Tingting, LIU Jiaren. β-Ionone suppresses breast cancer cell proliferation through the NF-κB pathway [J]. Journal of Practical Oncology, 2024, 38(4): 254-261.
[15]	SHAO Yuming, ZHU Kunbing, ZHANG Jie. Research progress of SP/NK-1R system in breast cancer [J]. Journal of Practical Oncology, 2024, 38(4): 268-272.

Mechanisms involved in liver metastasis of breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments